Presentation is loading. Please wait.

Presentation is loading. Please wait.

In vivo human models for the study of anticholinergic drugs

Published byLaure Lefèvre Modified over 5 years ago

Similar presentations

Presentation on theme: "In vivo human models for the study of anticholinergic drugs"— Presentation transcript:

1 In vivo human models for the study of anticholinergic drugs
Robert M. Naclerio, MD, Fuad M. Baroody, MD  Journal of Allergy and Clinical Immunology  Volume 95, Issue 5, Pages (May 1995) DOI: /S (95) Copyright © 1995 Mosby, Inc. Terms and Conditions

2 FIG. 1 Schematic drawing of nose and central nervous system. Stimulation of sensory nerves of nasal mucosa initiates a central neuronal reflex that affects both ipsilateral and contralateral nasal cavities via parasympathetic and sympathetic efferent pathways. Sensory stimulation can also lead to axonal reflexes, which affect ipsilateral nasal mucosa. Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

3 Fig. 2 Dose-response curves of secretion weight after placebo or different doses of ipratropium bromide. BASE, Baseline secretions; SAL, saline challenge; 0.02, 0.06, 0.19, 0.6, 1.7, and 5, doses of methacholine (mg) used for sequential challenges. Error bars are omitted for 21, 42, and 84 μg doses for purposes of clarity. All doses of ipratropium were more effective in inhibiting secretory response to methacholine than was placebo, and 168 μg dose was significantly more effective than other active treatments. (From Baroody FM, Majchel AM, Roecker MM, et al. Ipratropium bromide [Atrovent nasal spray] reduces the nasal response to methacholine. J Allergy Clin Immunol 1992;89: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

4 FIG. 3 Secretion weights after repetitive challenges with 0.19 mg of methacholine. Time after treatment of each challenge is displayed on abscissa. Data are presented as mean ± SEM of 24 subjects. * = p < 0.05 compared with placebo. The 42 μg dose of ipratropium bromide significantly reduced secretion weights at 15-minute, 30-minute, and 1-hour time points (p < 0.05). the 168 μg dose significantly decreased secretion weights from 15 minutes to 6 hours (p < 0.01). (From Wagenmann M, Baroody FM, Jankowski R, et al. Onset and duration of inhibition of ipratropium nasal spray on methacholine-induced nasal secretions. Clin Exp Allergy 1994;24;288-90). Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

5 FIG. 4 Effect of atropine premedication of both sides of nose on ipsilateral (panel A) and contralateral (panel B) responses after stimulation of ipsilateral nasal cavity with histamine. In both panels abscissa represents challenge protocal with the initial saline challenge (Sal) followed by increasing doses of histaming in mg. *p ≤ 0.05 compared with saline challenge within same curve and †p ≤ 0.05 compared with atropine. (From Baroody FM, Wagenmann M, Naclerio RM. A comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993;74: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

6 FIG. 4 Effect of atropine premedication of both sides of nose on ipsilateral (panel A) and contralateral (panel B) responses after stimulation of ipsilateral nasal cavity with histamine. In both panels abscissa represents challenge protocal with the initial saline challenge (Sal) followed by increasing doses of histaming in mg. *p ≤ 0.05 compared with saline challenge within same curve and †p ≤ 0.05 compared with atropine. (From Baroody FM, Wagenmann M, Naclerio RM. A comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993;74: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

7 FIG. 5 Effect of topical atropine premedication on ipsilateral changes after antigen challenge. Challenge protocal is shown on abscissa: B, Baseline; Dil, diluent challenge; 3.3, 33.3, and 333.3, doses of antigen used in PNU. Data represent mean ± SEM of nine volunteers. *p ≤ 0.01, **p ≤ 0.05 compared with diluent challenge. †p < 0.05 placebo vs atropine. (From Baroody FM, Ford S, Lichtenstein LM, et al. Physiologic responses and histamine release after nasal antigen challenge: effect of atropine. Am J Respir Crit Care Med 1994;149: Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

8 FIG. 5 Effect of topical atropine premedication on ipsilateral changes after antigen challenge. Challenge protocal is shown on abscissa: B, Baseline; Dil, diluent challenge; 3.3, 33.3, and 333.3, doses of antigen used in PNU. Data represent mean ± SEM of nine volunteers. *p ≤ 0.01, **p ≤ 0.05 compared with diluent challenge. †p < 0.05 placebo vs atropine. (From Baroody FM, Ford S, Lichtenstein LM, et al. Physiologic responses and histamine release after nasal antigen challenge: effect of atropine. Am J Respir Crit Care Med 1994;149: Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

9 FIG. 6 Bilateral secretory response after unilateral CDA nasal challenge. A, Both sides treated with placebo; B, atropine ipsilateral and placebo contralateral to challenge; C, placebo ipsilateral and atropine contralateral to challenge. (ipsi, Ipsilateral to CDA challenge; contra, contralateral to CDA challenge; pre dg, pre drug; post dg, post drug. (From Jankowski R, Philip G, Togias A, Naclerio R. Demonstration of bilateral cholinergic secretory response after unilateral nasal cold, dry air challenge. Rhinology 1993;31: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

10 FIG. 6 Bilateral secretory response after unilateral CDA nasal challenge. A, Both sides treated with placebo; B, atropine ipsilateral and placebo contralateral to challenge; C, placebo ipsilateral and atropine contralateral to challenge. (ipsi, Ipsilateral to CDA challenge; contra, contralateral to CDA challenge; pre dg, pre drug; post dg, post drug. (From Jankowski R, Philip G, Togias A, Naclerio R. Demonstration of bilateral cholinergic secretory response after unilateral nasal cold, dry air challenge. Rhinology 1993;31: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

11 FIG. 6 Bilateral secretory response after unilateral CDA nasal challenge. A, Both sides treated with placebo; B, atropine ipsilateral and placebo contralateral to challenge; C, placebo ipsilateral and atropine contralateral to challenge. (ipsi, Ipsilateral to CDA challenge; contra, contralateral to CDA challenge; pre dg, pre drug; post dg, post drug. (From Jankowski R, Philip G, Togias A, Naclerio R. Demonstration of bilateral cholinergic secretory response after unilateral nasal cold, dry air challenge. Rhinology 1993;31: ) Journal of Allergy and Clinical Immunology  , DOI: ( /S (95) ) Copyright © 1995 Mosby, Inc. Terms and Conditions

Download ppt "In vivo human models for the study of anticholinergic drugs"

Similar presentations

Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials  Javier Dibildox,

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials  Javier Dibildox,
Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance  Ulf Bengtsson, MD, PhDa, Tina W. Knutson,

Eosinophil cationic protein and histamine after intestinal challenge in patients with cow's milk intolerance  Ulf Bengtsson, MD, PhDa, Tina W. Knutson,
Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms 
Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a- induced bronchoconstriction  Nunzio Crimi, MD, Corrado Pagano, MD,

Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a- induced bronchoconstriction  Nunzio Crimi, MD, Corrado Pagano, MD,
Overcoming barriers to nonadherence in asthma treatment

Overcoming barriers to nonadherence in asthma treatment
Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: Comparison between human upper and lower airways  Jordi Roca-Ferrer, MSa,

Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: Comparison between human upper and lower airways  Jordi Roca-Ferrer, MSa,
Laboratory animal allergy

Laboratory animal allergy
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation  Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,

Dose-dependent effects of capsaicin nasal challenge: In vivo evidence of human airway neurogenic inflammation  Alvin M. Sanico, MDa, Satsuki Atsuta, MDa,
Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials  Javier Dibildox,

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials  Javier Dibildox,
Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.
Enhanced nasal cytokine production in human beings after in vivo challenge with diesel exhaust particles  David Diaz-Sanchez, PhD, Albert Tsien, MD, Adrian.

Enhanced nasal cytokine production in human beings after in vivo challenge with diesel exhaust particles  David Diaz-Sanchez, PhD, Albert Tsien, MD, Adrian.
Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD 

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD 
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 
Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen  Maria-Helena Terrien, MD, François Rahm, MD, Jean-Marc.

Similar presentations

Ads by Google